Comparison · NCT04328727-deaths
Eltrombopag vs Eltrombopag (Post-treatment Long Term Follow-up): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Eltrombopag vs Eltrombopag (Post-treatment Long Term Follow-up): deaths from any cause. Trial comparisons, record NCT04328727-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04328727-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0278 | 0.00492 | 0.142 | wilson | |
| Risk in group 2 | 0.0588 | 0.0163 | 0.191 | wilson | |
| Risk difference, group 1 minus group 2 | -0.031 | -0.165 | 0.0906 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.472 | 0.0448 | 4.97 | log | |
| Odds ratio, group 1 over group 2 | 0.457 | 0.0395 | 5.29 | log | |
| Number needed to treat, for one fewer death from any cause on Eltrombopag than on Eltrombopag (Post-treatment Long Term Follow-up) | 32.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Eltrombopag | Participants received eltrombopag in combination with r-ATG and CsA. | 1 | 36 | EG000 |
| Group 2 | Eltrombopag (Post-treatment Long Term Follow-up) | Deaths collected in the post- treatment long term follow-up period (starting from day 31 after last dose). No AEs were collected during this period | 2 | 34 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
All-cause mortality: from first dose of study treatment up to 2 years after last dose including post-treatment long term follow up period up to 3.1 years approximately. Serious and Other Adverse Events: from first dose of study treatment until 30 days after last dose up to 1.1 years approximately.
Source ClinicalTrials.gov
Trial
- Title
- Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
- NCT number
- NCT04328727
- Phases
- PHASE2
- Conditions
- Severe Aplastic Anemia (SAA)
- Interventions
- eltrombopag, rabbit anti-thymocyte globulin (r-ATG), cyclosporine A (CsA)
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2025-07-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04328727?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04328727-deaths